Dana-Farber Cancer Institute: Pancreatic Neoplasms trials

The registry lists 20 Pancreatic Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 4 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 5Phase 2 7No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk IndividualsRecruitingNCT06122896Early Phase 1
• Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD TrialRecruitingNCT05356117Not applicable
• Resilience and Equity in Aging, Cancer, and Health (REACH)RecruitingNCT04674267Not applicable
• Stereotactic Magnetic Resonance Guided Radiation TherapyRecruitingNCT04115254Not applicable
• EL CENTRO: Engaging Latinos in the Center of Cancer Treatment OptionsCompletedNCT03602885Not applicableResults posted
• Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic AdenocarcinomaTerminatedNCT03469258Phase 2Results posted
• Improving Informed Consent for Palliative ChemotherapyCompletedNCT02282722Not applicableResults posted
• Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic CancerCompletedNCT01273805Phase 2Results posted
• Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic CancerTerminatedNCT00889187Phase 1/2Results posted
• RAD001 in Previously Treated Patients With Metastatic Pancreatic CancerCompletedNCT00409292Phase 2Results posted
• Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
• Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate CancersCompletedNCT04330716Not applicable
• Niraparib in Patients With Pancreatic CancerCompletedNCT03601923Phase 2
• Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic CancerTerminatedNCT03520790Phase 1
• Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic CancerCompletedNCT03316599Phase 1
• Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
• Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized TherapyActive, not recruitingNCT03060720
• Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic CancerCompletedNCT00251355Phase 1
• Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic CancerCompletedNCT00137761Phase 2
• Tarceva and Capecitabine for Pancreatic CancerCompletedNCT00125021Phase 2